Page last updated: 2024-09-05

ly 353381 and transforming growth factor beta

ly 353381 has been researched along with transforming growth factor beta in 2 studies

Compound Research Comparison

Studies (ly 353381)	Trials (ly 353381)	Recent Studies (post-2010) (ly 353381)	Studies (transforming growth factor beta)	Trials (transforming growth factor beta)	Recent Studies (post-2010) (transforming growth factor beta)
70	12	15	49,119	560	17,610

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Farris, MR; Glasebrook, AL; Grese, TA; Heyman, RA; Lamph, WW; Palkowitz, AD; Risingsong, R; Sporn, MB; Suh, N; Williams, CR	1
Berchuck, A; Heyman, RA; Krajewski, S; Lamph, WW; Liby, K; Reed, JC; Rendi, MH; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR	1

Other Studies

2 other study(ies) available for ly 353381 and transforming growth factor beta

Article	Year
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:10 Topics: Animals; Anticarcinogenic Agents; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mammary Neoplasms, Experimental; Methylnitrosourea; Neoplasm Invasiveness; Nicotinic Acids; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Piperidines; Rats; Selective Estrogen Receptor Modulators; Stromal Cells; Tetrahydronaphthalenes; Thiophenes; Transforming Growth Factor beta	2002
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer research, 2004, May-15, Volume: 64, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Mammary Neoplasms, Experimental; NF-kappa B; Nicotinic Acids; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thiophenes; Transfection; Transforming Growth Factor beta	2004

Article

Year

Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:10

Topics: Animals; Anticarcinogenic Agents; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mammary Neoplasms, Experimental; Methylnitrosourea; Neoplasm Invasiveness; Nicotinic Acids; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Piperidines; Rats; Selective Estrogen Receptor Modulators; Stromal Cells; Tetrahydronaphthalenes; Thiophenes; Transforming Growth Factor beta

2002

The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.

Cancer research, 2004, May-15, Volume: 64, Issue:10

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Mammary Neoplasms, Experimental; NF-kappa B; Nicotinic Acids; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thiophenes; Transfection; Transforming Growth Factor beta

2004